Ποια είναι η τιμή για Applied Molecular Transport Inc. (AMTI)

Η τιμή για Applied Molecular Transport Inc. (AMTI) είναι $0.263

Ποια είναι η κεφαλαιοποίηση αγοράς για Applied Molecular Transport Inc. (AMTI)

Η κεφαλαιοποίηση αγοράς για Applied Molecular Transport Inc. (AMTI) είναι $9.26M

Applied Molecular Transport Inc. (AMTI) Τιμή και Κεφαλαιοποίηση Αγοράς

Applied Molecular Transport Inc. (AMTI), a biopharmaceutical company in the clinical development phase, was founded in 2010 and is based in South San Francisco, California. The firm is dedicated to discovering and advancing a pipeline of oral and respiratory biologic drug candidates, designed to address a variety of medical conditions including autoimmune, inflammatory, and metabolic diseases. Among its investigational treatments, AMT-101 stands out as the lead candidate. This orally administered, gastrointestinal (GI)-selective biologic, derived from rhIL-10, is presently in Phase II clinical trials for the management of ulcerative colitis and other related inflammatory indications. AMTI is also further developing AMT-126, another oral, GI-selective biologic that harnesses interleukin 22. This compound is currently undergoing Phase I clinical studies for the treatment of disorders stemming from impaired intestinal epithelial barrier function. The company's innovative technology platform allows for the creation and development of a broad spectrum of oral biologic therapeutic approaches, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics.

Η τιμή για AMTI	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$155,975 $9.26M	NVDA	$5.493T	+59,305,857.16%
$127,015 $9.26M	AAPL	$4.473T	+48,294,530.44%
$117,569 $9.26M	GOOG	$4.141T	+44,703,037.32%
$101,258 $9.26M	MSFT	$3.566T	+38,501,061.90%
$79,392.94 $9.26M	AMZN	$2.796T	+30,187,328.64%

Η τιμή για AMTI

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$155,975 $9.26M